Project Grant R37CA283552
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$650K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19111, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $127,629 to support research led by President and Fellows of Harvard College at the Harvard T.H. Chan School of Public Health. The overarching goal is to elucidate the role of both germline and somatic human leukocyte antigen (HLA) variations in cellular immunity and the efficacy of immune checkpoint inhibitor (ICI) monotherapy for patients with non-small cell lung cancer...
The National Cancer Institute (NCI) awarded a $3,787,956 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to New York University (NYU) School of Medicine. The grant, titled "Investigating and Targeting Replication Stress in Small Cell Lung Cancer," aims to advance the understanding of molecular mechanisms underlying DNA replication stress and identify novel therapeutic strategies to combat acquired chemoresistance in small cell lung cancer (SCLC). The research...
This Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop a new monoclonal antibody therapy to treat small cell lung cancer (SCLC). Specifically, the $194,013 award will fund the generation and testing of a mouse monoclonal antibody targeting an isoaspartylated form of the ELAVL4 protein, which is expressed on SCLC tumor cells. The research will be conducted by the University of Southern California over a 2-year period from...
The National Cancer Institute (NCI) has awarded a $154,400 Project Grant (CFDA 93.396 Cancer Biology Research) to The Broad Institute, Inc. to support research on activating the SLFN12 RNase enzyme's cytotoxic effects against cancer cells. The research aims to determine whether SLFN12 dimerization can induce tRNA-Leu-TAA degradation and cancer cell death, independent of the PDE3A protein. Experiments will test if high SLFN12 expression alone can trigger this cytotoxic response, and whether a...
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $548,915 to the Fred Hutchinson Cancer Center in Seattle, WA to conduct research into a novel tumor suppression pathway in small cell lung cancer (SCLC). The research aims to leverage genetically engineered mouse models and cellular systems to elucidate the biological roles of the SAPK/AP-1 pathway in SCLC tumor initiation and progression....
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $230,010 to the University of Chicago to conduct research aimed at understanding the drivers of metastasis in small cell lung cancer (SCLC). The project leverages the university's recently developed method to generate functionally viable pulmonary neuroendocrine cells (PNECs) from human pluripotent stem cells, which can be transformed to replicate key stages of SCLC from...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $216,972 to Temple University to conduct research focused on understanding and targeting the unique vulnerabilities that drive replication stress and G1/S transition issues in small cell lung cancer (SCLC). The research aims to elucidate the mechanistic role of low levels of the LMNA nuclear structural protein in causing increased replication stress in SCLC, as well as determine...
The National Cancer Institute (NCI) awarded a $1,408,844 Project Grant (CFDA 93.395 Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY to investigate the theranostic potential of Delta-Like Ligand 3 (DLL3)-targeting agents in high-grade neuroendocrine carcinomas of the lung (small cell lung cancer) and prostate (neuroendocrine prostate cancer). The project aims to utilize a DLL3-targeted radiolabeled monoclonal antibody for non-invasive diagnosis...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the Sloan-Kettering Institute for Cancer Research to investigate mechanisms through which deficiency of the SMARCA4 gene promotes metastasis in lung adenocarcinoma. The research aims to elucidate the role of the ROR2/p-GSK3bS9 signaling pathway in driving metastasis in SMARCA4-deficient lung cancer. Key activities include conducting RNA-seq, ChIP-seq, ATAC-seq, and mass...